# A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload

> **NCT00171821** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1784 (actual)

## Conditions studied

- Transfusion-dependent Iron Overload

## Interventions

- **DRUG:** Deferasirox

## Key facts

- **NCT ID:** NCT00171821
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2009-05
- **Final completion:** 2010-07
- **Target enrollment:** 1784 (ACTUAL)
- **Last updated:** 2020-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00171821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00171821, "A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00171821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*